clinical trials

Reform School

March 11, 2011

If you would understand why reform of our medical system is so difficult consider the case of the angiogenesis inhibitor Avastin. The drug had been used in combination with other therapies to treat metastatic breast cancer. “The FDA notified healthcare professionals and patients that it is recommending removing the breast cancer indication for bevacizumab (Avastin) […]